Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Opening Session Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




May
25
Today In Oncology
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo